Abstract
We know that within the complex mammalian gut is any number of metabolic biomes. The gut has been sometimes called the “second brain” within the “gut-brain axis”. A more informative term would be the gut-brain metabolic interactome, which is coined here to underscore the relationship between the digestive system and cognitive function or dysfunction as the case may be. Co-metabolism between the host and the intestinal microbiota is essential for life’s processes. How diet, lifestyle, antibiotics and other factors shape the gut microbiome constitutes a rapidly growing area of research. Conversely, the gut microbiome also affects mammalian systems. Metabolites of the gut-brain axis are potential targets for treatment and drug design since the interaction or biochemical interplay results in net metabolite production or end-products with either positive or negative effects on human health. This review explores the gut-brain metabolic interactome, with particular emphasis on drug design and treatment strategies and how commensal bacteria or their disruption lead to dysbiosis and the effect this has on neurochemistry. Increasing data indicate that the intestinal microbiome can affect neurobiology, from mental and even behavioral health to memory, depression, mood, anxiety, obesity, cravings and even the creation and maintenance of the blood brain barrier.
Keywords: Antibiotics, Microbiota, Neurotransmitters, Gut Brain axis, Metabolomics, Fecal Material Transplant, Signaling, Metabolic Crosstalk, Trimethylamine, Trimethylamine N-Oxide, Carnitine.
CNS & Neurological Disorders - Drug Targets
Title:The Co-Metabolism within the Gut-Brain Metabolic Interaction: Potential Targets for Drug Treatment and Design
Volume: 15 Issue: 2
Author(s): Mark Obrenovich, Rudolf Flückiger, Lorraine Sykes and Curtis Donskey
Affiliation:
Keywords: Antibiotics, Microbiota, Neurotransmitters, Gut Brain axis, Metabolomics, Fecal Material Transplant, Signaling, Metabolic Crosstalk, Trimethylamine, Trimethylamine N-Oxide, Carnitine.
Abstract: We know that within the complex mammalian gut is any number of metabolic biomes. The gut has been sometimes called the “second brain” within the “gut-brain axis”. A more informative term would be the gut-brain metabolic interactome, which is coined here to underscore the relationship between the digestive system and cognitive function or dysfunction as the case may be. Co-metabolism between the host and the intestinal microbiota is essential for life’s processes. How diet, lifestyle, antibiotics and other factors shape the gut microbiome constitutes a rapidly growing area of research. Conversely, the gut microbiome also affects mammalian systems. Metabolites of the gut-brain axis are potential targets for treatment and drug design since the interaction or biochemical interplay results in net metabolite production or end-products with either positive or negative effects on human health. This review explores the gut-brain metabolic interactome, with particular emphasis on drug design and treatment strategies and how commensal bacteria or their disruption lead to dysbiosis and the effect this has on neurochemistry. Increasing data indicate that the intestinal microbiome can affect neurobiology, from mental and even behavioral health to memory, depression, mood, anxiety, obesity, cravings and even the creation and maintenance of the blood brain barrier.
Export Options
About this article
Cite this article as:
Obrenovich Mark, Flückiger Rudolf, Sykes Lorraine and Donskey Curtis, The Co-Metabolism within the Gut-Brain Metabolic Interaction: Potential Targets for Drug Treatment and Design, CNS & Neurological Disorders - Drug Targets 2016; 15 (2) . https://dx.doi.org/10.2174/1871527315666160202123107
DOI https://dx.doi.org/10.2174/1871527315666160202123107 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antimicrobial Peptides and Peptidomimetics - Potent Therapeutic Allies for Staphylococcal Infections
Current Pharmaceutical Design Editorial: “Ah, Wherefore with Infection Should he Live?”: Microbial Virulence Factors in Diabetic Foot Ulceration
Current Vascular Pharmacology Prevalence of Nasal Colonization with Staphylococcus aureus in Patients with Rheumatoid Arthritis
Current Rheumatology Reviews Methadone and the Heart: What the Clinician Needs to Know
Current Drug Abuse Reviews Indications of Anti-Inflammatory Drugs in Cardiac Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Platelet-Derived Chemokines in Atherogenesis: What’s New?
Current Vascular Pharmacology Use of Oritavancin (Novel New Lipoglycopeptide) in the Treatment of Prosthetic Joint Infections (PJI): A Possible Alternative Novel Approach to a Difficult Problem
Infectious Disorders - Drug Targets Older Adults Prescribed Methadone: A Review of the Literature Across the Life Span from Opiate Initiation to Methadone Maintenance Treatment
Current Drug Abuse Reviews Prevention of Cardiovascular Complications in the Marfan Syndrome
Vascular Disease Prevention (Discontinued) Genome Variability in Gram-Positive Pathogenic Bacteria - Impact on Virulence and Evolution
Current Genomics The Escalating Challenge of Vancomycin Resistance in Staphylococcus aureus
Current Drug Targets - Infectious Disorders Heart Valve Lesions In The Antiphospholipid Syndrome
Current Rheumatology Reviews Active Metabolites Resulting from Decarboxylation, Reduction and Ester Hydrolysis of Parent Drugs
Current Drug Metabolism Structural Insights into Chitinolytic Enzymes and Inhibition Mechanisms of Selective Inhibitors
Current Pharmaceutical Design Potential Therapeutic Application of Chondroitin Sulfate/Dermatan Sulfate
Current Drug Discovery Technologies Para-prosthetic Leaks Following Mitral Valve Replacement: Case Analysis on a 20-year Period
Current Cardiology Reviews N-Containing Ag(I) and Hg(II) Complexes: A New Class of Antibiotics
Current Topics in Medicinal Chemistry Human Heart Failure: A Proteomics Perspective
Current Proteomics Heart Failure in South America
Current Cardiology Reviews Allergic Bronchopulmonary Aspergillosis: AllA Radiologist Needs To Know
Current Pediatric Reviews